NR565 ADVANCED PHARMACOLOGY MIDTERM 2026/2027 |
130 Q&A Question Bank | Chamberlain | Pass Guaranteed -
A+ Graded
SECTION 1: FOUNDATIONS IN PHARMACOLOGY –
PHARMACOKINETICS & PHARMACODYNAMICS (25 QUESTIONS)
Q1: A 68-year-old patient with chronic heart failure is prescribed oral furosemide 40 mg
daily. The nurse practitioner recognizes that after beginning this medication, the time
required to reach steady-state plasma concentration is determined primarily by which
pharmacokinetic parameter?
A. Volume of distribution
B. Bioavailability
C. Half-life [CORRECT]
D. Therapeutic index
Correct Answer: C
Rationale: Steady-state concentration (Css) is achieved after approximately 4 to 5
half-lives of a drug, regardless of dose or dosing interval. The half-life (t½) represents
the time required for plasma drug concentration to decrease by 50% and is the primary
determinant of how quickly a drug accumulates to steady state. Volume of distribution
affects the extent of distribution but not the time to steady state. Bioavailability
determines the fraction of drug reaching systemic circulation but does not govern the
rate of accumulation. Therapeutic index is a safety measure (TD50/ED50) and unrelated
to kinetic timing.
Q2: A patient taking warfarin for atrial fibrillation is started on amiodarone for rhythm
control. The nurse practitioner anticipates an increased INR because amiodarone
inhibits CYP2C9 and CYP3A4. This interaction exemplifies which pharmacokinetic
principle?
A. Induction of phase II metabolism
B. Inhibition of first-pass metabolism
,C. Inhibition of hepatic microsomal enzyme activity [CORRECT]
D. Increased renal tubular secretion
Correct Answer: C
Rationale: Amiodarone is a potent inhibitor of multiple CYP450 enzymes including
CYP2C9 and CYP3A4, which are responsible for metabolizing the more potent
S-enantiomer of warfarin. By inhibiting hepatic microsomal enzyme activity, amiodarone
reduces warfarin clearance, leading to increased plasma concentrations and elevated
INR. This is not an induction effect (which would decrease drug levels), nor is it primarily
related to first-pass metabolism or renal tubular secretion.
Q3: A 55-year-old patient with a history of alcohol use disorder is prescribed lorazepam
for acute alcohol withdrawal. The nurse practitioner understands that in patients with
chronic alcohol use, which pharmacokinetic phase is most significantly affected,
potentially requiring dosage adjustment?
A. Absorption due to gastric mucosal damage
B. Distribution due to altered protein binding
C. Metabolism due to CYP450 enzyme induction [CORRECT]
D. Excretion due to decreased glomerular filtration
Correct Answer: C
Rationale: Chronic alcohol consumption induces CYP450 enzymes (particularly CYP2E1
and CYP3A4), accelerating the metabolism of many drugs including benzodiazepines.
This may necessitate higher initial doses during acute withdrawal; however, upon
alcohol cessation, enzyme activity normalizes and previously adequate lorazepam
doses may become excessive. While absorption and distribution may be minimally
affected, the most clinically significant and well-documented alteration is in hepatic
metabolism via enzyme induction.
Q4: A nurse practitioner is prescribing a highly lipophilic drug to a patient with
significant adipose tissue. Which statement accurately describes the expected impact
on this drug's pharmacokinetic profile?
A. The drug will have a smaller volume of distribution and shorter duration of action
B. The drug will accumulate in fat tissue, prolonging elimination and duration of action
[CORRECT]
C. The drug will exhibit increased renal clearance due to enhanced glomerular filtration
,D. The drug will have enhanced bioavailability due to increased first-pass metabolism
Correct Answer: B
Rationale: Lipophilic drugs readily distribute into adipose tissue, which serves as a deep
compartment or reservoir. This increases the apparent volume of distribution (Vd) and
creates a concentration gradient that slowly releases drug back into systemic
circulation, thereby prolonging elimination half-life and duration of action. Renal
clearance is not enhanced; in fact, lipophilic drugs typically require hepatic metabolism
before renal elimination. First-pass metabolism is unrelated to body composition.
Q5: A patient with chronic kidney disease (CKD) stage 4 is prescribed gabapentin for
neuropathic pain. The nurse practitioner calculates a reduced dose because gabapentin
relies primarily on which elimination pathway?
A. Hepatic oxidation via CYP3A4
B. Glucuronidation in the liver
C. Renal excretion of unchanged drug [CORRECT]
D. Biliary excretion and enterohepatic recirculation
Correct Answer: C
Rationale: Gabapentin undergoes minimal hepatic metabolism and is eliminated almost
entirely by renal excretion as unchanged drug. In CKD stage 4 (eGFR 15-29 mL/min),
renal clearance is markedly impaired, necessitating dose reduction and/or extended
dosing intervals to prevent accumulation and neurotoxicity (sedation, dizziness, ataxia).
Hepatic pathways and biliary excretion are not clinically significant for gabapentin
elimination.
Q6: The nurse practitioner is reviewing first-pass metabolism with a patient starting oral
propranolol. Which statement best explains why the oral dose of propranolol is
considerably higher than its intravenous equivalent?
A. Oral propranolol undergoes extensive hepatic extraction and metabolism before
reaching systemic circulation [CORRECT]
B. Oral propranolol is poorly absorbed from the gastrointestinal tract
C. Oral propranolol binds extensively to plasma proteins, reducing free drug
concentration
D. Oral propranolol is rapidly excreted by the kidneys before therapeutic levels are
achieved
, Correct Answer: A
Rationale: Propranolol is a classic example of a drug with high hepatic extraction ratio
and extensive first-pass metabolism. When administered orally, a significant portion is
metabolized by the liver before reaching systemic circulation, resulting in low
bioavailability (~25-30%). Consequently, oral doses must be substantially higher than IV
doses to achieve equivalent systemic exposure. Propranolol is actually well-absorbed
from the GI tract; the limitation is presystemic hepatic metabolism, not absorption,
protein binding, or renal excretion.
Q7: A patient with a gastric pH of 2.0 ingests a weakly acidic drug (pKa 4.0). The nurse
practitioner understands that ion trapping principles predict which distribution
outcome?
A. The drug will be predominantly ionized in the stomach and poorly absorbed
B. The drug will be predominantly non-ionized in the stomach and readily absorbed
[CORRECT]
C. The drug will be trapped in the stomach due to complete ionization
D. The drug will require an active transport mechanism for gastric absorption
Correct Answer: B
Rationale: According to the Henderson-Hasselbalch equation, when environmental pH <
pKa (2.0 < 4.0), weak acids exist predominantly in the non-ionized (protonated) form.
Only the non-ionized, lipid-soluble form readily crosses biological membranes.
Therefore, this weakly acidic drug will be largely non-ionized in the acidic gastric
environment, facilitating passive diffusion across gastric mucosa and absorption into
systemic circulation. Ion trapping occurs when pH > pKa for weak acids (or pH < pKa for
weak bases), favoring ionized forms that cannot easily cross membranes.
Q8: A nurse practitioner is teaching a patient about steady-state drug concentration.
The patient asks why their digoxin level is checked after 1 week rather than
immediately. The nurse practitioner's best response is based on which principle?
A. Steady-state is reached when drug absorption equals drug distribution
B. Steady-state occurs when the rate of drug administration equals the rate of
elimination [CORRECT]
C. Steady-state requires completion of all phase I and phase II metabolic reactions
D. Steady-state is achieved when the drug binds to all available receptor sites
130 Q&A Question Bank | Chamberlain | Pass Guaranteed -
A+ Graded
SECTION 1: FOUNDATIONS IN PHARMACOLOGY –
PHARMACOKINETICS & PHARMACODYNAMICS (25 QUESTIONS)
Q1: A 68-year-old patient with chronic heart failure is prescribed oral furosemide 40 mg
daily. The nurse practitioner recognizes that after beginning this medication, the time
required to reach steady-state plasma concentration is determined primarily by which
pharmacokinetic parameter?
A. Volume of distribution
B. Bioavailability
C. Half-life [CORRECT]
D. Therapeutic index
Correct Answer: C
Rationale: Steady-state concentration (Css) is achieved after approximately 4 to 5
half-lives of a drug, regardless of dose or dosing interval. The half-life (t½) represents
the time required for plasma drug concentration to decrease by 50% and is the primary
determinant of how quickly a drug accumulates to steady state. Volume of distribution
affects the extent of distribution but not the time to steady state. Bioavailability
determines the fraction of drug reaching systemic circulation but does not govern the
rate of accumulation. Therapeutic index is a safety measure (TD50/ED50) and unrelated
to kinetic timing.
Q2: A patient taking warfarin for atrial fibrillation is started on amiodarone for rhythm
control. The nurse practitioner anticipates an increased INR because amiodarone
inhibits CYP2C9 and CYP3A4. This interaction exemplifies which pharmacokinetic
principle?
A. Induction of phase II metabolism
B. Inhibition of first-pass metabolism
,C. Inhibition of hepatic microsomal enzyme activity [CORRECT]
D. Increased renal tubular secretion
Correct Answer: C
Rationale: Amiodarone is a potent inhibitor of multiple CYP450 enzymes including
CYP2C9 and CYP3A4, which are responsible for metabolizing the more potent
S-enantiomer of warfarin. By inhibiting hepatic microsomal enzyme activity, amiodarone
reduces warfarin clearance, leading to increased plasma concentrations and elevated
INR. This is not an induction effect (which would decrease drug levels), nor is it primarily
related to first-pass metabolism or renal tubular secretion.
Q3: A 55-year-old patient with a history of alcohol use disorder is prescribed lorazepam
for acute alcohol withdrawal. The nurse practitioner understands that in patients with
chronic alcohol use, which pharmacokinetic phase is most significantly affected,
potentially requiring dosage adjustment?
A. Absorption due to gastric mucosal damage
B. Distribution due to altered protein binding
C. Metabolism due to CYP450 enzyme induction [CORRECT]
D. Excretion due to decreased glomerular filtration
Correct Answer: C
Rationale: Chronic alcohol consumption induces CYP450 enzymes (particularly CYP2E1
and CYP3A4), accelerating the metabolism of many drugs including benzodiazepines.
This may necessitate higher initial doses during acute withdrawal; however, upon
alcohol cessation, enzyme activity normalizes and previously adequate lorazepam
doses may become excessive. While absorption and distribution may be minimally
affected, the most clinically significant and well-documented alteration is in hepatic
metabolism via enzyme induction.
Q4: A nurse practitioner is prescribing a highly lipophilic drug to a patient with
significant adipose tissue. Which statement accurately describes the expected impact
on this drug's pharmacokinetic profile?
A. The drug will have a smaller volume of distribution and shorter duration of action
B. The drug will accumulate in fat tissue, prolonging elimination and duration of action
[CORRECT]
C. The drug will exhibit increased renal clearance due to enhanced glomerular filtration
,D. The drug will have enhanced bioavailability due to increased first-pass metabolism
Correct Answer: B
Rationale: Lipophilic drugs readily distribute into adipose tissue, which serves as a deep
compartment or reservoir. This increases the apparent volume of distribution (Vd) and
creates a concentration gradient that slowly releases drug back into systemic
circulation, thereby prolonging elimination half-life and duration of action. Renal
clearance is not enhanced; in fact, lipophilic drugs typically require hepatic metabolism
before renal elimination. First-pass metabolism is unrelated to body composition.
Q5: A patient with chronic kidney disease (CKD) stage 4 is prescribed gabapentin for
neuropathic pain. The nurse practitioner calculates a reduced dose because gabapentin
relies primarily on which elimination pathway?
A. Hepatic oxidation via CYP3A4
B. Glucuronidation in the liver
C. Renal excretion of unchanged drug [CORRECT]
D. Biliary excretion and enterohepatic recirculation
Correct Answer: C
Rationale: Gabapentin undergoes minimal hepatic metabolism and is eliminated almost
entirely by renal excretion as unchanged drug. In CKD stage 4 (eGFR 15-29 mL/min),
renal clearance is markedly impaired, necessitating dose reduction and/or extended
dosing intervals to prevent accumulation and neurotoxicity (sedation, dizziness, ataxia).
Hepatic pathways and biliary excretion are not clinically significant for gabapentin
elimination.
Q6: The nurse practitioner is reviewing first-pass metabolism with a patient starting oral
propranolol. Which statement best explains why the oral dose of propranolol is
considerably higher than its intravenous equivalent?
A. Oral propranolol undergoes extensive hepatic extraction and metabolism before
reaching systemic circulation [CORRECT]
B. Oral propranolol is poorly absorbed from the gastrointestinal tract
C. Oral propranolol binds extensively to plasma proteins, reducing free drug
concentration
D. Oral propranolol is rapidly excreted by the kidneys before therapeutic levels are
achieved
, Correct Answer: A
Rationale: Propranolol is a classic example of a drug with high hepatic extraction ratio
and extensive first-pass metabolism. When administered orally, a significant portion is
metabolized by the liver before reaching systemic circulation, resulting in low
bioavailability (~25-30%). Consequently, oral doses must be substantially higher than IV
doses to achieve equivalent systemic exposure. Propranolol is actually well-absorbed
from the GI tract; the limitation is presystemic hepatic metabolism, not absorption,
protein binding, or renal excretion.
Q7: A patient with a gastric pH of 2.0 ingests a weakly acidic drug (pKa 4.0). The nurse
practitioner understands that ion trapping principles predict which distribution
outcome?
A. The drug will be predominantly ionized in the stomach and poorly absorbed
B. The drug will be predominantly non-ionized in the stomach and readily absorbed
[CORRECT]
C. The drug will be trapped in the stomach due to complete ionization
D. The drug will require an active transport mechanism for gastric absorption
Correct Answer: B
Rationale: According to the Henderson-Hasselbalch equation, when environmental pH <
pKa (2.0 < 4.0), weak acids exist predominantly in the non-ionized (protonated) form.
Only the non-ionized, lipid-soluble form readily crosses biological membranes.
Therefore, this weakly acidic drug will be largely non-ionized in the acidic gastric
environment, facilitating passive diffusion across gastric mucosa and absorption into
systemic circulation. Ion trapping occurs when pH > pKa for weak acids (or pH < pKa for
weak bases), favoring ionized forms that cannot easily cross membranes.
Q8: A nurse practitioner is teaching a patient about steady-state drug concentration.
The patient asks why their digoxin level is checked after 1 week rather than
immediately. The nurse practitioner's best response is based on which principle?
A. Steady-state is reached when drug absorption equals drug distribution
B. Steady-state occurs when the rate of drug administration equals the rate of
elimination [CORRECT]
C. Steady-state requires completion of all phase I and phase II metabolic reactions
D. Steady-state is achieved when the drug binds to all available receptor sites
